View all news

    Treatment with RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in ProgressionFree Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion MutationPositive Non-Small Cell Lung Cancer

    07/17/2023
    Download(opens in new window)PDF 224 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com